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Oxygen deﬁcit (hypoxia) is a major feature of cardiorespiratory diseases characterized by diaphragm dysfunction, yet the putative
role of hypoxic stress as a driver of diaphragm dysfunction is understudied. We explored the cellular and functional consequences
of sustained hypoxic stress in a mouse model. Adult male mice were exposed to 8 hours of normoxia, or hypoxia (FiO2 = 0.10) with
or without antioxidant pretreatment (N-acetyl cysteine, 200mg/kg i.p.). Ventilation and metabolism were measured. Diaphragm
muscle contractile function, myoﬁbre size and distribution, gene expression, protein signalling cascades, and oxidative stress
(TBARS) were determined. Hypoxia caused pronounced diaphragm muscle weakness, unrelated to increased respiratory muscle
work. Hypoxia increased diaphragm HIF-1α protein content and activated MAPK, mTOR, Akt, and FoxO3a signalling
pathways, largely favouring protein synthesis. Hypoxia increased diaphragm lipid peroxidation, indicative of oxidative stress.
FoxO3 and MuRF-1 gene expression were increased. Diaphragm 20S proteasome activity and muscle ﬁbre size and distribution
were unaﬀected by acute hypoxia. Pretreatment with N-acetyl cysteine substantially enhanced cell survival signalling, prevented
hypoxia-induced diaphragm oxidative stress, and prevented hypoxia-induced diaphragm dysfunction. Hypoxia is a potent driver
of diaphragm weakness, causing myoﬁbre dysfunction without attendant atrophy. N-acetyl cysteine protects the hypoxic
diaphragm and may have application as a potential adjunctive therapy.
1. Introduction
The diaphragm is the principal muscle of inspiration, an inte-
gral part of the thoracic “pump”musculature, responsible for
eﬀective lung ventilation. Diaphragm muscle weakness can
present in respiratory disease, and it is a strong predictor of
poor outcome in clinical patients, particularly those requir-
ing mechanical ventilation [1]. Hypoxia (oxygen deﬁcit)
commonly presents as a feature in many acute respiratory
conditions including acute respiratory distress syndrome,
ventilator-induced lung injury, ventilator-associated lung
injury, and acute lung injury, conditions where diaphragm
muscle weakness is typically observed [2–6]. Interventions
serving to prevent or suppress diaphragm muscle weakness
in hypoxaemic respiratory patients could have substantially
beneﬁcial eﬀects for patient outcome. Whereas this is an area
of intense research, it appears that the potentially deleterious
role of hypoxic stress in the development and manifestation
of diaphragm muscle weakness has been overshadowed by
other factors such as mechanical unloading (inactivity),
injury, infection, and sepsis, despite the potential for signiﬁ-
cant cellular redox modulation during oxygen deﬁcit, and
the well-recognized dominant role of oxidative stress as a
contributory factor in respiratory and skeletal muscle wast-
ing in critically ill patients [7–12].
It is established that exposure to chronic sustained
hypoxia results in respiratory myoﬁbre atrophy and mus-
cle weakness associated with a time-dependent progressive
oxidative stress [13–16]. We recently demonstrated that
acute sustained hypoxia (8 hours of exposure) is suﬃcient
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to weaken mouse diaphragm peak force-generating capacity
by ~30% [17, 18]. Our ﬁnding provides a basis for the
hypothesis that acute hypoxia-induced diaphragm dysfunc-
tion could be an underrecognized and yet major factor con-
tributing to diaphragm weakness in the critical care setting
[18], and perhaps during exposure to environmental hypoxia
at high altitude [19–21].
It is recognized that antioxidants have considerable ther-
apeutic eﬃcacy in the treatment of respiratory-related disor-
ders featuring redox imbalance and overt oxidative stress,
such as acute lung injury, sepsis, chronic obstructive pulmo-
nary disease, chronic bronchitis, lung ﬁbrosis, and cystic
ﬁbrosis [22–30]. N-acetyl cysteine (NAC) is a free radical
scavenger, which boosts the synthesis of the endogenous
antioxidant glutathione as well as other antioxidant systems.
Chronic NAC supplementation has been shown to prevent
diaphragm muscle weakness in animal models of chronic
sustained hypoxia [16] and chronic intermittent hypoxia
[31, 32]. Of interest, acute respiratory distress syndrome
patients are in a prooxidant state, which can be improved
by NAC supplementation, by increasing glutathione, thiol
molecules, and antioxidant defences [33]. The muscles of
breathing, like other striated muscles, are highly dependent
on redox balance for optimal function [15, 16, 34, 35]. We
reasoned that acute hypoxic stress is detrimental to muscle
function. If so, antioxidant intervention may alleviate acute
hypoxia-induced diaphragm dysfunction, a ﬁnding which if
it translates to humans could prove useful in the treatment
of hypoxaemic respiratory patients in the clinic.
Therefore, we sought to further explore the cellular
mechanisms underpinning acute hypoxia-induced dia-
phragm weakness and establish if pretreatment with NAC
at the outset of acute hypoxic exposure prevents or amelio-
rates diaphragm muscle weakness. The aims of our study
were to (1) conﬁrm the deleterious eﬀects of acute sustained
hypoxia on mouse diaphragm force-frequency relationship;
(2) determine the whole body integrative ventilatory and
metabolic strategies adopted by mice during acute hypoxic
exposure; (3) examine protein signalling pathways in dia-
phragm muscle, putatively aﬀected by acute hypoxic stress;
(4) examine gene expression changes in the diaphragm asso-
ciated with atrophy and autophagy processes; (5) determine
if 20S proteasome activity is increased by acute hypoxic stress
in the diaphragm; (6) determine if diaphragm myoﬁbre size
and distribution are aﬀected by acute hypoxia; (7) determine
if acute hypoxia causes diaphragm oxidative stress; and (8)
explore the eﬃcacy of NAC pretreatment in ameliorating
diaphragm functional responses to acute sustained hypoxia.
2. Methods
2.1. Ethical Approval. All protocols involving animals
described in this study were performed under licence from
the Irish Government in accordance with the National and
EU legislation following institutional animal research ethics
committee approval.
2.2. Animal Model. Models of acute hypoxia were gener-
ated using adult male C57BL6/J mice (Envigo, UK). Mice
(~14 weeks of age) were placed in environmental plethys-
mography chambers (Buxco Ltd., USA), at room tempera-
ture, in which ambient oxygen levels were measured and
adjusted to desired levels (gas analyzer, ML206, AD Instru-
ments, UK). Mice were exposed to one, four, or eight hours
of hypoxia (fraction of inspired oxygen, FiO2= 0.10) or
normoxia (FiO2= 0.21) (n = 8 per group). An additional
group of mice (n = 8) were each given a single injection
of N-acetyl cysteine (NAC; 200mg/kg; i.p.) immediately
prior to 8 hours of hypoxia exposure.
2.3. Whole Body Plethysmography. Breathing parameters,
including respiratory frequency (fR), tidal volume (VT), and
minute ventilation (VE) were measured on a breath-by-
breath basis. O2 consumption (VO2) and CO2 production
(VCO2) were monitored over the course of the gas exposure,
serving as an index of whole body metabolism. Gas concen-
trations entering and leaving the plethysmography chambers
were sampled using a gas analyzer (ML206, AD Instru-
ments). The respiratory exchange ratio (VCO2/VO2) and
the ventilatory equivalent for carbon dioxide (VE/VCO2)
were determined oﬄine. Following 8 hours of gas exposure,
animals were euthanized using a rising concentration of
CO2 until narcosis, followed immediately by cervical disloca-
tion to conﬁrm euthanasia. Core body temperature was deter-
mined immediately postmortem, via insertion of a probe
(TH-8 Thermalert, Physitemp Instruments, Inc., USA); body
mass was recorded. Diaphragm muscles were quickly excised
and either immediately used for functional analysis or imme-
diately snap frozen in liquid nitrogen and stored at −80°C
until further processing for molecular analysis.
2.4. Muscle Physiology: Experimental Setup. Experiments
were performed on diaphragm muscle preparations derived
from the 3 groups of mice: normoxia, hypoxia, and hyp-
oxia +NAC. Once excised, diaphragm muscles were placed
in a holding bath containing continuously gassed (95% O2/
5% CO2) Krebs solution at room temperature. A longitudinal
strip of diaphragm muscle with rib and central tendon intact
was prepared and mounted vertically in a tissue holder by
attaching the rib to a ﬁxed hook and connecting the tendon
to a force transducer (Aurora Scientiﬁc, USA) for the assess-
ment of isometric contractile parameters. The preparation
was housed in a tissue bath of Krebs solution at 35°C, gassed
with 95% O2/5% CO2.
2.5. Muscle Physiology: Experimental Protocol.Muscle prepa-
rations were set to optimal length by adjusting the length of
the tissue bundle between repeated twitch contractions until
peak twitch force was determined. The relationship between
stimulation frequency and tetanic force generation (force-
frequency relationship) was assessed by stimulating the mus-
cle strip at increasing stimulation frequencies from 10Hz to
160Hz and recording the force generated at each frequency.
Forces recorded at each frequency were then normalized to
the estimated cross-sectional area of the muscle tissue bun-
dle, and data were expressed as speciﬁc force in N/cm2.
2.6. Gene Expression: RNA Extraction and Preparation. Total
RNA was extracted from 20–70mg of frozen diaphragm
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tissue homogenized using a general laboratory homogenizer
(Omni-Inc., USA) in the presence of Tripure Isolation
Reagent (Roche Diagnostics Ltd., UK). The manufacturer’s
instructions were followed with the addition of a chloroform
wash step during phase separation. Next, RNA was treated
with TURBO DNA-free Kit (Life Technologies, Bio-Sciences,
Ireland) in accordance with the manufacturer’s instructions.
The quantity and purity of RNA were assessed using a Nano-
drop 1000 (Thermo Scientiﬁc, USA) and spectrophotometry.
The integrity of RNA was assessed by visualization of clear
18S and 28S ribosomal RNA bands using an agarose gel
electrophoresis system (E-gel, Life Technologies).
2.7. Gene Expression: Reverse Transcription. Diaphragm
muscle RNA was reverse transcribed using Transcriptor First
Strand cDNA Synthesis Kit (Roche Diagnostics Ltd.) in
accordance with the manufacturer’s instructions.
2.8. Gene Expression: qRT-PCR. cDNA was ampliﬁed using
Realtime ready Catalog or Custom Assays (Roche Diagnos-
tics Ltd.) and Fast Start Essential DNA Probe Master (Roche
Diagnostics Ltd.) in 20μl reactions (5μl cDNA and 15μl
master mix) using the LightCycler 96 (Roche Diagnostics
Ltd.) on 96-well plates, in accordance with the manufac-
turer’s instructions. All reactions were performed in dupli-
cate and reverse transcriptase negatives, RNA negatives,
and cDNA negatives (no template), and plate calibrator con-
trols were used on every plate. Diaphragm gene expression
was normalized to a reference gene, hprt1, to compensate
for variations in input amounts of RNA/cDNA and the eﬃ-
ciency of reverse transcription. In preliminary studies, several
candidate reference genes were screened, and in consider-
ation of temporal and gas (hypoxia) exposures, hprt1 was
found to be most stable. The relative expression of genes
was calculated using the ΔΔCT method, that is, normalized
expression of the gene of interest to that of the reference gene,
with changes in expression displayed as a fold change relative
to the control group.
2.9. Cell Signalling: Protein Extraction and Quantiﬁcation.
Frozen muscle samples were removed from storage at
−80°C, weighed and homogenized on ice in ice-cold 2.5%
w/vmodiﬁed radioimmunoprecipitation assay (RIPA) buﬀer
(1X RIPA, deionized H2O, 200mM sodium ﬂuoride, 100mM
phenylmethylsulfonylﬂuoride (PMSF), 1X protease inhibitor
cocktail, and 2X phosphatase inhibitor cocktail) using a gen-
eral laboratory homogenizer (Omni-Inc., USA). Following
20-minute lyse time on ice, with vortexing every 4 minutes,
samples were centrifuged in a U-320R centrifuge (Boeckel
& Co, Germany) at 14,000 RPM at 4°C for 20 minutes to sep-
arate insoluble cellular fractions from the protein homoge-
nates. The protein containing supernatant was separated
from the insoluble pellet in each sample, and these were
stored at −80°C. The pellets were discarded.
The protein concentration of each sample was deter-
mined using a bicinchoninic acid (BCA) protein quantiﬁca-
tion assay (Pierce Biotechnology, (Fisher Scientiﬁc), Ireland)
as per the manufacturer’s instructions, at a dilution of 1 : 3.
2.10. Cell Signalling: Hypertrophy, Atrophy and HIF
Signalling, and Protein/Phosphoprotein Content Assays. Cell
signalling assays were performed using an Akt signalling
panel–phospho-Akt, phospho-p70S6K, phospho-S6RP, and
phospho-GSK-3β; Phospho-/Total mTOR; Phospho-
FOXO3a; a MAP Kinase phosphoprotein panel–phospho-
p-38, phospho-ERK1/2, and phospho-JNK; and total
HIF-1α (MesoDiscovery, USA).
The assays measure the protein or phosphorylated pro-
tein content of signalling proteins listed above. The sandwich
immunoassays were either in multiplex format (Mesoscale
Discovery, USA) allowing the measurement of up to 4
proteins/phosphoproteins in one well, or singleplex assay
which allowed measurement of the content of one protein/
phosphoprotein per well. The assay was carried out in accor-
dance with the manufacturer’s instructions. Brieﬂy, samples
were loaded onto the 96-well plate and incubated to allow
the proteins of interest to be captured by their speciﬁc
capture antibodies. Each well was then washed and incu-
bated in a detection antibody solution. The detection anti-
bodies, speciﬁc for each protein of interest, are conjugated
with an electrochemiluminescent compound, or tag. The
detection antibodies bind to the captured proteins of interest,
which are bound to their speciﬁc capture antibodies, on the
distinct spots on the bottom surface of the well. This com-
pletes the antibody-protein-antibody sandwich. The well
was then washed again, and read buﬀer was added, creating
the correct chemical environment for electrochemilumines-
cence. The plate was loaded into the MSD SECTOR Imager
(a specialized spectrophotometer from Mesoscale) where a
voltage is rapidly applied to the distinct working electrodes
on the plate spots resulting in the tags conjugated to the anti-
bodies attached to those electrodes emitting light, which is
read by the imager at 620nm. The intensity of this emitted
light from each spot, separated both temporally and spatially,
provides a quantitativemeasurement for each protein of inter-
est in the sample. This assay was performed on diaphragm
samples from control, hypoxia, and hypoxia +NAC groups.
A series of dilutions with muscle sample was also assayed
as a control to demonstrate increased luminescence with
increased protein content added to the well for each assay.
2.11. Thiobarbituric Acid Reactive Substances (TBARS) Assay.
TBARS are degradation products of fats which are routinely
used as a marker of lipid peroxidation, an indirect measure-
ment of oxidative stress. Malondialdehyde (MDA) of a
known concentration was used to generate a standard curve.
Next, 50μl of thiobarbituric acid (TBA, 50mM) was added to
50μl of diaphragm muscle homogenate (as described above
in section 2.9), and the solution was incubated for 60 mins
at 97°C. Samples were subsequently cooled on ice, and 75μl
of methanol : 1mM NaOH (91 : 9) was added to the solution.
Samples were then centrifuged at 704g, and 70μl of the resul-
tant supernatant was added per well in a black 96-well plate.
The plate was read in a SpectraMax-M3 spectrophotometer
(Molecular Devices, USA) using 523/553 excitation/emission
settings, and data were compared with standards. Data are
expressed as nM TBARS per mg of protein in the sample,
determined by BCA assay.
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2.12. Proteasome Activity Assay. Chymotrypsin-like 20S
proteasome activity was measured via ﬂuorescence in a spec-
trophotometric assay as per the manufacturer’s instructions
(Abcam, UK) using a Spectramax M3 spectrophotometer
(Molecular Devices, USA). The assay employs a peptide sub-
strate tagged to AMC. In the presence of proteasome activity,
the AMC tag is released and ﬂuoresced. The kit includes a
positive control in the form of Jurkat cell lysate with high
proteasome activity and a speciﬁc proteasome inhibitor
MG-132, which suppresses all proteolytic activity attributed
to proteasomes, thus allowing the diﬀerentiation of protea-
some activity from other protease activity in the sample. This
assay was performed on diaphragm samples from normoxia,
hypoxia, and hypoxia +NAC groups on a white 96-well plate;
all samples and positive controls were assayed with and with-
out the proteasome inhibitor. The samples, positive controls,
and standards were added to the 96-well plate. Inhibitor was
added to assigned wells (an equal volume of assay buﬀer was
added to the uninhibited wells), and proteasome substrate
was added to all wells except the standards. The plate was
then incubated at 37°C in the spectrophotometer (protected
from light) for one hour while ﬂuorometric readings were
made kinetically over that time at Ex/Em=350/440 nm.
There was a slight nonlinearity to the reaction kinetics at
the beginning due to the lag time it takes for the reaction to
mix and warm to 37°C. Readings were made from the linear
range of the reaction. Nonproteasome activity was then
subtracted from total activity to give proteasome activity.
One unit of proteasome activity is deﬁned as the amount
of proteasome which generates 1 nmol of AMC per minute
at 37°C.
2.13. Muscle Immunohistochemistry. Sections of hemidiaph-
ragm from control (n = 6) and hypoxia (n = 6) mice were
mounted on cubes of liver to facilitate subsequent tissue
sectioning. Samples were coated in optimum cutting temper-
ature (OCT; VWR International, Dublin, Ireland) embed-
ding medium and then quickly frozen in isopentane (Sigma
Aldrich, Wicklow, Ireland) cooled in liquid nitrogen. Tissue
samples were subsequently stored at −80°C for structural
analysis at a later time. Serial transverse muscle sections
(10μm) were generated using a cryostat (Leica CM3050;
Leica Microsystems, Nussloch, Germany) at −22°C and
mounted on polylysine-coated glass slides (VWR Interna-
tional, Dublin, Ireland). Slides were immersed for 15 minutes
in phosphate-buﬀered saline (PBS, 0.01M) containing 1%
bovine serum albumin (BSA). After PBS washes (3× 5 min-
ute), slides were next immersed for 30 minutes in PBS
containing 5% normal goat serum (Sigma Aldrich, Wicklow,
Ireland). Slides then underwent PBS washes (3× 5 minute)
prior to the application of the primary antibody (rabbit
anti-laminin, 1 : 200; Sigma Aldrich, Wicklow, Ireland),
diluted in PBS and 1% BSA. Slides were then incubated over-
night at 4°C in a humidity chamber. The following day, slides
were washed with PBS (3× 5 minutes) before application of
the secondary antibody (FITC-conjugated goat anti-rabbit;
1.250, Sigma Aldrich, Wicklow, Ireland), which was diluted
in PBS and 1% BSA. Slides were incubated for 1 hour at room
temperature in the dark.
Using an Olympus BX51 microscope and an Olympus
DP71 camera, muscle sections were viewed at ×10 magni-
ﬁcation and images were captured for analysis. For each
animal, several images from separate muscle sections were
captured for analysis. We employed a square test frame of
600× 600μm, with inclusion and exclusion boundaries,
which was placed randomly over each image [32]. To deter-
mine the size of diaphragm muscle ﬁbres, the individual ﬁbre
perimeters were manually highlighted using Image J software
allowing the determination of ﬁbre cross-sectional area and
minimal Feret’s diameter. The coeﬃcient of variation of these
parameters was also computed. Data generated from
multiple sections were ﬁrst averaged for each animal before
computing group means. Relative frequency histograms were
constructed to illustrate the distribution of muscle ﬁbre size
in sections from control and hypoxia mice.
2.14. Data and Statistical Analysis. GraphPad Prism (Graph-
Pad Software Inc., USA) was used to perform statistical anal-
ysis. Following tests for normality and equal variance in the
data sets, the Student t-tests were performed for comparisons
between two groups: normoxia and hypoxia. For multiple
groups, one-way or two-way ANOVA (with Tukey’s and
Bonferroni post hoc tests, resp.) were used as appropriate.
Statistical signiﬁcance was taken at the level of p < 0 05.
3. Results
3.1. Diaphragm Force. The mouse diaphragm force-
frequency relationship following exposure to 8 hours of nor-
moxia, hypoxia, and hypoxia +NAC is displayed in Figure 1.
Speciﬁc force-generating capacity of the diaphragm muscle
increased as a function of stimulation frequency (10–160Hz;
frequency: p < 0 0001, two-way ANOVA). Speciﬁc force gen-
eration over the range of stimulation frequencies tested was
signiﬁcantly lower in the hypoxia group compared with the
normoxia group (gas: p = 0 0112); this weakness was most
prominent at higher stimulation frequencies. A single i.p.
injection of NAC prior to hypoxic exposure completely
prevented hypoxia-induced diaphragm muscle weakness
(p < 0 0001 versus hypoxia). Indeed, the hypoxia +NAC
group developed the highest forces, exceeding control values
over the range of stimulation frequencies (Figure 1).
3.2. Metabolism and Breathing. CO2 production over 8 hours
of exposure to normoxia (control) and hypoxia is shown in
Figure 2(a). CO2 production was signiﬁcantly lower in the
hypoxia group compared with the normoxia group (two-
way ANOVA; gas: p < 0 0001) over the duration of the gas
exposures, revealing a hypometabolic response to sustained
hypoxia in mice.
Postmortem body temperature following gas treatments
in all 3 groups is shown in Figure 2(b). Compared with mice
in the normoxia group, body temperatures were lower in
mice exposed to hypoxia (p < 0 0001, unpaired t test) and
hypoxia +NAC (p = 0 0105, unpaired t test with Welch’s
correction). There was no diﬀerence in body temperature
between hypoxia and hypoxia +NAC groups.
4 Oxidative Medicine and Cellular Longevity
Figure 3(a) shows mouse respiratory VE, a product
of fR and VT, throughout the duration of normoxia (control)
and hypoxia. VE was increased (two-way ANOVA; gas:
p < 0 001) after 10 mins of hypoxia compared with nor-
moxia, but returned to levels equivalent to normoxia by
20 mins and remained at levels similar to normoxia for
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Figure 1: Mouse diaphragmmuscle force-frequency relationship following 8 hours of exposure to normoxia (control), hypoxia, or hypoxia +
NAC. Diaphragm-speciﬁc force (mean± SEM) expressed as force per unit cross-sectional area of muscle (N/cm2) as a function of stimulation
frequencies ranging between 10 and 160Hz; n= 6–8 per group. Data were compared statistically by two-way (gas treatment× stimulation
frequency) ANOVA; ∗p < 0 05 and ∗∗p < 0 01. Bonferroni’s post hoc multiple comparisons test hypoxia +NAC versus hypoxia.
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Figure 2: (a) Carbon dioxide production over 8 hours of breathing in mice exposed to normoxia (control) or hypoxia. Carbon dioxide
production (mean± SEM) in mice expressed as ml per minute per gram body mass (ml/min/g) over the 480-minute (8 hour) period of
exposure to either normoxia (FiO2 = 0.21, n = 6) or hypoxia (FiO2 = 0.10, n = 7); two-way (time× gas treatment) ANOVA and Bonferroni’s
multiple comparisons test. ∗∗∗p < 0 001 and ∗∗p < 0 01 compared with corresponding normoxic values. (b) Postmortem body
temperatures in mice following 8 hours of exposure to normoxia (control), hypoxia, or hypoxia +NAC. Postmortem body temperatures
(mean± SEM) of mice exposed to 8 hours of normoxia (FiO2 = 0.21, n = 6), hypoxia (FiO2 = 0.10, n = 7), or hypoxia +NAC (200mg/kg i.p.
at FiO2 = 0.10, n = 4). ∗∗∗∗p < 0 0001, unpaired t test compared with control; ∗p = 0 0105, unpaired t test with Welch’s correction
compared with control.
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the remainder of the 8-hour exposure to hypoxia. Thus,
beyond the initial transient hypoxic ventilatory response,
ventilation was largely unchanged during hypoxic exposure
in mice.
The ventilatory equivalent for carbon dioxide (VE/VCO2)
over 8 hours of exposure to normoxia (control) and hypoxia
is shown in Figure 3(b).VE/VCO2 was signiﬁcantly increased
in the hypoxic group upon gas exposure compared
with the control group, and it remained elevated over the
course of the 8 hours of gas exposure (two-way ANOVA;
gas: p < 0 0001), indicative of the development of a
hypoxia-induced hyperventilation (arising due to hypometa-
bolism with maintained ventilation).
Figure 3(c) shows the respiratory exchange ratio
(VCO2/VO2) over 8 hours of exposure to normoxia (control)
and hypoxia. There was no signiﬁcant eﬀect of exposure to
hypoxia on VCO2/VO2 over the course of the 8 hours of
gas exposure compared with control.
3.3. HIF-1α: Gene Expression and Protein Content. There was
no signiﬁcant diﬀerence in HIF-1α mRNA expression
between groups (data not shown). Figure 4 shows HIF-1α
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Figure 3: Minute ventilation (VE), ventilatory equivalent for carbon dioxide (VE/VCO2), and respiratory exchange ratio (RER; VCO2/VO2)
during 8 hours of exposure to normoxia (control) or hypoxia. (a) Minute ventilation (mean± SEM) expressed as ml per min per gram body
mass (ml/min/g) over the 480-minute (8 hour) period of exposure to either normoxia (FiO2 = 0.21, n = 6) or hypoxia (FiO2 = 0.10, n = 7);
two-way ANOVA (time× gas treatment) and Bonferroni’s multiple comparisons test, ∗∗∗p < 0 001 compared with corresponding normoxic
value. (b) Ventilatory equivalent ratio (mean± SEM) in mice over the 480-minute (8 hour) period of exposure to either normoxia
(FiO2 = 0.21, n = 6) or hypoxia (FiO2 = 0.10, n = 7); two-way ANOVA (time× gas treatment) and Bonferroni’s multiple comparisons test,
∗∗∗p < 0 001 and ∗∗p < 0 01 compared with corresponding normoxic value. (c) Respiratory exchange ratio (mean± SEM) in mice over the
480-minute (8 hour) period of exposure to either normoxia (FiO2 = 0.21, n = 6) or hypoxia (FiO2 = 0.10, n = 7); two-way ANOVA
(time× gas treatment).
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protein content in diaphragmmuscle frommice exposed to 8
hours of normoxia, hypoxia, or hypoxia +NAC. Hypoxia sig-
niﬁcantly increased HIF-1α protein content compared with
the control group (p = 0 0019; unpaired t test). HIF-1α pro-
tein content was further increased in hypoxia +NAC com-
pared with normoxia (p < 0 0001) and was also signiﬁcantly
higher in hypoxia +NAC compared with the hypoxia group
(p = 0 0332).
3.4. Cell Signalling: Akt Pathway. Phospho-Akt protein
content in diaphragm muscle from mice exposed to 8
hours of normoxia, hypoxia, or hypoxia +NAC is shown
in Figure 5(a). Exposure to hypoxia signiﬁcantly increased
phospho-Akt protein content compared with the control
group (p = 0 0109; unpaired t test). Phospho-Akt protein
content was further increased in hypoxia +NAC compared
with normoxia (p = 0 0001) and was also signiﬁcantly
higher in hypoxia +NAC compared with the hypoxia
group (p = 0 0004).
Figure 5(b) shows phospho-p70S6K protein content
in diaphragm muscle from mice exposed to 8 hours of
normoxia, hypoxia, or hypoxia +NAC. Exposure to hypoxia
had no signiﬁcant eﬀect on phospho-p70S6K protein con-
tent compared with normoxia. However, hypoxia +NAC
increased phospho-p70S6K protein content compared
with the control group (p = 0 0019) and also increased
phospho-p70S6K protein content above the level of the
hypoxia group (p = 0 0616).
Figure 5(c) shows phospho-S6RP protein content in dia-
phragm muscle from mice exposed to 8 hours of normoxia,
hypoxia, or hypoxia +NAC. Exposure to hypoxia signiﬁ-
cantly increased phospho-S6RP protein content compared
with the control group (p = 0 0434). Hypoxia +NAC also
increased phospho-S6RP protein content compared with
the control group (p = 0 0099), but there was no diﬀerence
between the hypoxia and hypoxia +NAC groups.
Figure 5(d) shows phospho-GSK-3β protein content in
diaphragm muscle from mice exposed to 8 hours of
normoxia, hypoxia, or hypoxia +NAC. Exposure to hypoxia
signiﬁcantly increased phospho-GSK-3β protein content
compared with the control group (p = 0 0009). Hypoxia +
NAC increased phospho-GSK-3β protein content further
still compared with the control group (p = 0 0006), but
there was no diﬀerence between the hypoxia and hyp-
oxia +NAC groups.
3.5. Cell Signalling: mTOR Pathway. Figure 6(a) shows
mTOR protein content in diaphragm muscle from mice
exposed to 8 hours of normoxia, hypoxia, or hypoxia +
NAC. Exposure to hypoxia signiﬁcantly increased mTOR
protein content compared with the control group (p =
0 0107). Hypoxia +NAC, however, did not increase mTOR
protein content compared with the control group, and
mTOR protein content was signiﬁcantly lower in the
hypoxia +NAC group compared with the hypoxia group
(p = 0 0020).
Figure 6(b) shows phospho-mTOR protein content in
diaphragm muscle from mice exposed to 8 hours of nor-
moxia, hypoxia, or hypoxia +NAC. Exposure to hypoxia
signiﬁcantly increased phospho-mTOR protein content
compared with the normoxia group (p = 0 0123). Phospho-
mTOR protein content was further increased in the hyp-
oxia +NAC group compared with the control group (p =
0 0001) and was also signiﬁcantly higher than the hypoxia
group (p = 0 0067).
3.6. Cell Signalling: FoxO3a Pathway. Figure 6(c) shows
phospho-FoxO3a protein content in diaphragm muscle
from mice exposed to 8 hours of normoxia, hypoxia, or
hypoxia +NAC. Exposure to hypoxia signiﬁcantly increased
phospho-FoxO3a protein content compared with the nor-
moxia group (p = 0 0002). Phospho-FoxO3a protein content
was further increased in the hypoxia +NAC group compared
with the control group (p < 0 0001) and was also signiﬁcantly
higher than the hypoxia group (p = 0 0024).
3.7. Cell Signalling: JNK, p38, and ERK1/2 Pathways. Phos-
pho-JNK protein content in diaphragm muscle from mice
exposed to 8 hours of normoxia, hypoxia, or hypoxia +
NAC is shown in Figure 7(a). Exposure to hypoxia signiﬁ-
cantly increased phospho-JNK protein content compared
with the normoxia group (p = 0 0120). Phospho-JNK protein
content was further increased in the hypoxia +NAC group
compared with the control group (p = 0 0058) and was also
signiﬁcantly higher than the hypoxia group (p = 0 0108).
Figure 7(b) shows phospho-p38 protein content in dia-
phragm muscle from mice exposed to 8 hours of normoxia,
hypoxia, or hypoxia +NAC. Exposure to hypoxia increased
phospho-p38 protein content compared with the normoxia
group (p = 0 0515). Phospho-p38 protein content was fur-
ther increased in the hypoxia +NAC group compared with
the control group (p = 0 0030) and was also signiﬁcantly
higher than the hypoxia group (p = 0 0092).
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Figure 4: Mouse diaphragm HIF-1α protein content following
8 hours of exposure to normoxia (control), hypoxia, or hypoxia
+NAC. Diaphragm HIF-1α protein content (mean± SEM)
expressed as signal/μg of total protein (corrected for background
signal) following exposure to either normoxia (control;
FiO2 = 0.21, n = 6), hypoxia (FiO2 = 0.10, n = 7), or hypoxia +NAC
(200mg/kg i.p. at FiO2 = 0.10);
∗p = 0 0332, ∗∗p = 0 0019, and
∗∗∗∗p < 0 0001; unpaired t tests.
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Phospho-ERK1/2 protein content in diaphragm mus-
cle from mice exposed to 8 hours of normoxia, hypoxia,
or hypoxia +NAC is shown in Figure 7(c). Hypoxia sig-
niﬁcantly increased phospho-ERK1/2 protein content
compared with the normoxia group (p = 0 0406). Phospho-
ERK1/2 protein content was increased further in the
hypoxia +NAC group compared with the control group
(p = 0 0020) and was also signiﬁcantly higher than the
hypoxia group (p = 0 0046).
3.8. Atrophy and Autophagy Gene Expression. Figure 8 shows
expression data in diaphragm muscle for genes related to
atrophy and autophagy. There were no signiﬁcant changes
in FoxO-1, Atrogin-1, LC3B, BNIP3, or GABARAPL3
mRNA expression between groups (one-way ANOVA and
Tukey’s post hoc test). FoxO-1, Atrogin-1, and BNIP3
displayed nonsigniﬁcant trends toward increased expression
levels following increasing durations of hypoxic exposure
(1, 4, and 8 hours). Both FoxO-3 andMuRF-1mRNA expres-
sion was signiﬁcantly increased following 8 hours of hypoxic
exposure compared with control (p < 0 05, one-way ANOVA
and Tukey’s post hoc test) (Figures 8(b) and 8(d), resp.).
3.9. Oxidative Stress: TBARS Concentration. Data for dia-
phragm TBARS concentration (a marker of lipid peroxida-
tion) in normoxia, hypoxia, and hypoxia +NAC groups are
shown in Figure 9. TBARS concentration was signiﬁcantly
increased following exposure to hypoxia compared with
normoxia (p = 0 0076). TBARS concentration was signiﬁ-
cantly lower in NAC+hypoxia compared with hypoxia (p
< 0 0001) and also signiﬁcantly lower compared with the
normoxia group (p = 0 0030).
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Figure 5: Mouse diaphragm phospho-Akt (S473), phospho-p70S6K (T389), phospho-S6RP (S235/236), and phospho-GSK-3β protein
contents following 8 hours of exposure to normoxia (control), hypoxia, or hypoxia +NAC. (a) Diaphragm phospho-Akt (S473)
protein content (mean± SEM) expressed as signal/μg of total protein (corrected for background signal); n = 8 per group. ∗p = 0 0109,
∗∗∗∗p = 0 0001, and ∗∗∗p = 0 0004; unpaired t tests. (b) Diaphragm phospho-p70S6K (T389) protein content (mean± SEM) expressed as
signal/μg of total protein (corrected for background signal); n = 8 per group. ∗∗p = 0 0019; unpaired t test. (c) Diaphragm phospho-S6RP
(S235/236) protein content (mean± SEM) expressed as signal/μg of total protein (corrected for background signal); n = 8 per group.
∗p = 0 0434 and ∗∗p = 0 0099; unpaired t tests. (d) Diaphragm phospho-GSK-3β protein content (mean± SEM) expressed as signal/μg
of total protein (corrected for background signal); n = 8 per group. ∗∗∗∗p = 0 0006 and ∗∗∗p = 0 0009; unpaired t tests.
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3.10. Chymotrypsin-Like Proteasome Activity. Figure 10
shows diaphragm muscle chymotrypsin-like proteasome
activity in normoxia and hypoxia groups. There was no sig-
niﬁcant diﬀerence in chymotrypsin-like proteasome activity
between the two groups.
3.11. Diaphragm Muscle Fibre Size and Distribution. Repre-
sentative immunoﬂuorescence images of diaphragm muscles
from mice exposed to normoxia and hypoxia are shown in
Figures 11(a) and 11(b). There was no signiﬁcant diﬀerence
in the mean minimal Feret’s diameter (Figure 11(c)) or mean
cross-sectional area of ﬁbres (Figure 11(d)) between the two
groups. The coeﬃcient of variation of these indices was also
equivalent in control and hypoxia muscles (Figures 11(e)
and 11(f)). There was no shift in the relative frequency distri-
bution of ﬁbres in hypoxia compared with normoxia
(Figures 11(f) and 11(g)).
4. Discussion
The main ﬁndings of this study are the following: (1) Acute
hypoxic stress over several hours causes diaphragm muscle
weakness; (2) Diaphragm dysfunction is unrelated to
enhanced respiratory muscle work during hypoxic exposure,
since ventilation is unchanged in mice exposed to sustained
hypoxia; (3) Acute hypoxic stress stabilized diaphragm
HIF-1α protein and activated MAPK, mTOR, Akt, and
FoxO3a signalling pathways, favouring protein synthesis;
(4) Autophagy gene expression was unaﬀected by acute hyp-
oxia, but FoxO3 and MuRF-1 atrogene expression was pro-
gressively increased during hypoxic exposure without eﬀect
on diaphragm 20S proteasome activity; (5) Acute hypoxia
increased diaphragm TBARS concentration indicative of oxi-
dative stress; (6) Acute hypoxia did not aﬀect diaphragm
myoﬁbre size or distribution; (7) NAC pretreatment strongly
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Figure 6: Mouse diaphragm mTOR, phospho-mTOR, phospho-ERK1/2, and phospho-FOXO3a protein contents following 8 hours of
exposure to normoxia (control), hypoxia, or hypoxia +NAC. (a) Diaphragm mTOR protein content (mean± SEM) expressed as signal/μg
of total protein (corrected for background signal); n = 7 − 8 per group. ∗p = 0 0107 and ∗∗p = 0 0020; unpaired t tests. (b) Diaphragm
phospho-mTOR protein content (mean± SEM) expressed as signal/μg of total protein (corrected for background signal); n = 7 − 8 per
group. ∗p = 0 0123, ∗∗p = 0 0067, and ∗∗∗p = 0 0001; unpaired t tests. (c) Diaphragm phospho-FOXO3a protein content (mean± SEM)
expressed as signal/μg of total protein (corrected for background signal); n = 7 − 8 per group. ∗∗p = 0 0024, ∗∗∗p = 0 0002, and
∗∗∗∗p < 0 0001; unpaired t tests.
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potentiated many of the endogenous cell survival signalling
responses to acute hypoxic stress and reversed diaphragm
oxidative stress; (8) Antioxidant pretreatment with NAC
prevented acute hypoxia-induced diaphragm dysfunction.
4.1. Muscle Function. This study conﬁrms our previous
report [17], revealing that acute sustained hypoxia causes
pronounced diaphragm muscle weakness. Our experimental
approach was to study diaphragm performance ex vivo under
standardized conditions. In this way, we determined that
weakness is intrinsic to diaphragm muscle ﬁbres, as we con-
trolled the stimulation frequency. The approach allowed us
to reestablish optimal oxygen and acid-base conditions for
the study of muscle performance. Therefore, diaphragm
function was assessed at normal pH, whereas the persistent
hyperventilation associated with hypoxia exposure results
in a respiratory alkalosis and elevated blood pH, which are
likely to cause further perturbation to respiratory muscle
function in vivo. Our data reveal that the force-generating
capacity of diaphragm from hypoxic animals is intrinsically
weak, especially at high stimulation frequencies, which corre-
spond to activation of the muscle during airway protective
behaviours [36]. Decreased peak force-generating capacity
is linked to poor prognosis in respiratory patients [1]. Oxy-
gen was provided abundantly in the ex vivo preparation
allowing comparison of normoxia and hypoxia groups under
similar conditions. We concede that whereas the hypoxia
group was revealed as having decreased force-generating
capacity compared with the normoxia group, we did not
extend the study to determine how the hypoxia group would
have compared with the normoxia group under conditions of
bath hypoxia. For example, exposure to chronic sustained
hypoxia has been shown to improve tolerance to a subse-
quent severe hypoxic stimulus [37] revealing that hypoxic
adaptation in respiratory muscle can result in some protec-
tive outcomes relevant to the prevailing stimulus of oxygen
deﬁcit. Our data highlight the potential for acute hypoxic
stress to adversely aﬀect diaphragm performance, which has
relevance to respiratory patients, particularly in the critical
care setting [1], and may have implications for individuals
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Figure 7: Mouse diaphragm phospho-JNK and phospho-p38 protein contents following 8 hours of exposure to normoxia (control), hypoxia,
or hypoxia +NAC. (a) Diaphragm phospho-JNK protein content (mean± SEM) expressed as signal/μg of total protein (corrected for
background signal); n = 8 per group. ∗p = 0 0120, ∗∗p = 0 0108, and ∗∗∗p = 0 0058; unpaired t tests. (b) Diaphragm phospho-p38 protein
content (mean± SEM) expressed as signal/μg of total protein (corrected for background signal); n= 6–8 per group. ∗∗p = 0 0092 and
∗∗∗p = 0 0030; unpaired t tests. (c) Diaphragm phospho-ERK1/2 protein content (mean± SEM) expressed as signal/μg of total protein
(corrected for background signal); n= 5–8 per group. ∗p = 0 0406, ∗∗∗p = 0 0020, and ∗∗p = 0 0046; unpaired t tests.
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Figure 8: Mouse diaphragm muscle atrophy and autophagy gene expression following exposure to normoxia (control) or 1, 4, or 8 hours of
hypoxia. Fold changes in mRNA expression (relative to the control (normoxia) group) for (a) FoxO-1; (b) FoxO-3; (c) Atrogin-1; (d)MuRF-1;
(e) LC3B; (f) BNIP3; and (g) GABARAPL3; mean± SEM, n= 7–8 per group. ∗p < 0 05 versus control, one-way ANOVA and Tukey’s post hoc
test following 8 hours of exposure to normoxia and 1, 4, and 8 hours of exposure to hypoxia.
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at high altitude [19, 20]. We acknowledge that further assess-
ments of diaphragm function in vivo are required, where
respiratory muscle performance can be considered in the
context of an integrative multisystem response to hypoxia
(e.g., blood ﬂow and neural drive), to lend further credence
to our hypothesis that hypoxia is a driver of respiratory mus-
cle dysfunction.
Antioxidant pretreatment with NAC prior to hypoxic
exposure completely rescued the diaphragm from acute
hypoxia-induced diaphragm weakness. Indeed, notwith-
standing hypoxic exposure, NAC supplementation enhanced
muscle force-generating capacity above control levels. The
ﬁnding is reminiscent of a study showing that NAC treat-
ment immediately after the initiation of 6 hours of mechani-
cal ventilation completely prevented the development of
mechanical ventilation-induced diaphragmatic weakness
[8]. Of interest, in the latter study, NAC did not suppress
autophagy, rather it augmented autophagosome formation
suggesting that NAC exerts its beneﬁcial eﬀects on
ventilator-induced diaphragm dysfunction via stimulation
of autophagy (excess ROS can inhibit autophagy), which
appears to be a beneﬁcial adaptive response in the diaphragm
to the physiological stress of mechanical ventilation, rather
than representing a contributing factor to the development
of diaphragm dysfunction [8]. NAC has also been shown to
protect the diaphragm from the damaging eﬀects of
controlled mechanical ventilation including diaphragmatic
oxidative stress and proteolysis, as well as controlled
mechanical ventilation-induced contractile dysfunction
[38]. We have previously reported beneﬁcial eﬀects of NAC
in ameliorating diaphragm protein carbonylation, which
presents progressively in response to exposure to chronic
sustained hypoxia [16]. Indeed, protein carbonylation under-
pins the loss of skeletal muscle mass in a number of chronic
conditions [39] suggesting that NAC and other antioxidants
could have widespread utility as adjunctive therapies in skel-
etal muscle disease. Of interest, NAC also proved eﬃcacious
in preventing diaphragm muscle weakness and fatigue in a
rat model of chronic intermittent hypoxia modelling sleep
apnoea [32].
4.2. Metabolism. Acute hypoxic stress decreased metabo-
lism in mice, as evident from the rapid and sustained
reduction in CO2 production during hypoxia, as well as
the reduction in postmortem body temperature following
hypoxia. Interestingly, body temperature was reduced to
an equivalent level in the hypoxia +NAC group revealing
that the beneﬁcial eﬀect of NAC on hypoxic diaphragm
performance is unlikely related to an inﬂuence on the
hypoxic hypometabolic/hypothermic state and associated
alkalosis caused by the reduction in CO2 production con-
comitant with maintained ventilation, that is, hypoxic hyper-
ventilation. It is therefore conceivable to consider that the
beneﬁcial eﬀects of NAC relate instead to direct antioxidant
and/or signalling eﬀects in muscle.
It is also noteworthy that minute ventilation was rela-
tively unchanged over the 8 hours of hypoxic exposure in
comparison with control animals. This reveals that dia-
phragm activity is not increased due to a hypoxia-induced
increase in ventilatory drive (common to other mammals),
and so increased muscle activity during hypoxic stress is
not a contributory factor to the development of hypoxia-
induced diaphragm weakness, although it may be a further
aggravating factor during acute hypoxic stress in humans.
Our study in mice reveals the potential for diaphragmmuscle
weakness related to direct hypoxic (redox) stress of muscle
ﬁbres [16]. The hypometabolic response causes a relative
hyperventilation evident from the hypoxia-induced increase
in the ventilatory equivalent for carbon dioxide. The ensuing
alkalosis (which is achieved in humans during exposure to
hypoxia by way of enhanced ventilation with no change in
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Figure 9: Mouse diaphragm muscle thiobarbituric acid reactive
substances (TBARS) concentration following 8 hours of exposure
to normoxia (control), hypoxia, or hypoxia +NAC. TBARS
concentration in diaphragm muscle (mean± SEM) expressed as
nM TBARS per mg of protein following exposure to either
normoxia (FiO2 = 0.21), hypoxia (FiO2 = 0.10), or hypoxia +NAC
(200mg/kg i.p. at FiO2 = 0.10); n = 8 per group. ∗∗p < 0 01 and
∗∗∗p < 0 0001; unpaired t test with Welch’s correction.
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Figure 10: Mouse diaphragm muscle chymotrypsin-like
proteasome activity following 8 hours of exposure to normoxia
(control) or hypoxia. Chymotrypsin-like proteasome activity in
diaphragm muscle (mean± SEM) expressed as a rate of AMC tag
release from peptide substrate (pmol/min/mg of protein) following
exposure to either normoxia (control; FiO2 = 0.21) or hypoxia
(FiO2 = 0.10); n = 8 per group. There was no signiﬁcant diﬀerence
between the two groups (unpaired t test).
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Figure 11: Mouse diaphragm muscle ﬁbre size and distribution following exposure to 8 hours of normoxia (control) or hypoxia. (a)
Representative images of mouse diaphragm muscle immunoﬂuorescently labelled for laminin to highlight individual ﬁbres from animals
exposed to 8 hours of normoxia (control, FiO2 = 0.21) and hypoxia (FiO2 = 0.10). (b) Group data for mean minimal Feret’s diameter. (c)
Group data for mean muscle ﬁbre cross-sectional area. (d) Group data for coeﬃcient of variation of diaphragm muscle ﬁbre size measured
by minimal Feret’s diameter. (e) Group data for coeﬃcient of variation of diaphragm muscle ﬁbre size measured by cross-sectional area.
Data in (b–e) expressed as mean± SEM; there were no signiﬁcant diﬀerences between groups (n = 6 per group; unpaired Student’s t-tests).
(f) and (g) Relative frequency distribution of diaphragm muscle ﬁbres measured by minimal Feret’s diameter (f) and cross-sectional area (g).
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metabolism) may be a factor of relevance for diaphragm per-
formance in vivo. Of interest, the respiratory exchange ratio
was unchanged during exposure to hypoxia suggesting that
there was not a hypoxia-induced switch in metabolic sub-
strate preference away from lipids.
4.3. Hypoxia Signalling. HIF-1α protein content was
increased in the diaphragm following 8 hours of hypoxia.
This is not altogether surprising given that HIF-1α protein
accumulation is indirectly proportional to cytosolic oxygena-
tion, although muscle-speciﬁc and temporal responses have
been reported in respiratory muscles in response to chronic
sustained hypoxia [15, 16]. Reactive oxygen species can
induce HIF-1α expression, but this eﬀect can be dependent
on exposure time, and reactive oxygen species can exert the
opposite eﬀect over prolonged periods, thus creating some
uncertainty regarding how swings in cellular redox balance
aﬀect HIF-1α expression [40–43]. One might have expected
that NAC, as an antioxidant, would inﬂuence hypoxia-
induced increase in HIF-1α protein content. However, HIF-
1α is responsive to redox balance within the intracellular
environment and reducing conditions can stabilize HIF-1α.
Moreover, NAC-induced increases in cellular glutathione
can elevate HIF-1α expression [44–47]. In our study, pre-
treatment with NAC prior to hypoxic exposure enhanced
HIF-1α protein content in diaphragm muscle compared with
hypoxia alone. In view of the protective eﬀect of NAC on dia-
phragm force-generating capacity, this suggests that HIF-1α
stabilization was a component of the adaptive response of
muscle to hypoxic challenge. Indeed, it has been reported
that HIF-1α contributes to the neuroprotective eﬀect of
NAC in an ischaemic stroke model of transient cerebral
ischaemia in rats [47].
4.4. Hypertrophy/Atrophy Signalling. We examined the
protein and/or phosphoprotein content of various proteins
associated with signalling pathways involved in the balance
between cell survival and death and protein balance
(hypertrophy/atrophy) in diaphragm muscle (summarized
in Figure 12).
4.5. Prohypertrophy/Cell Survival Signalling
4.5.1. Akt Pathway. Akt, particularly the Akt/mTOR path-
way, is central to the control of the hypertrophic/atrophic
balance in muscle, acting in a phosphorylation-dependent
manner as a key regulator of downstream eﬀectors involved
in modulating cell growth and survival. Activated (phosphor-
ylated) Akt is predominantly prohypertrophic, via inhibition
of atrophic signals and promotion of hypertrophic signals. In
our study, phosphorylated (active) Akt (phospho-Akt) pro-
tein content was increased following acute hypoxia exposure
and enhanced further still by NAC supplementation. It has
been previously demonstrated that under certain conditions
hypoxia can activate Akt and it is suggested that hypoxia-
induced Akt activation may play a role in protection against
apoptosis [48–51]. Similarly, in our model, it would appear
that acute hypoxia-induced Akt activation is a beneﬁcial
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Figure 12: Schematic depicting the various cell survival signalling pathways explored in this study. Green arrows indicate activation, and red
lines indicate inhibition in diaphragm muscle following exposure to acute hypoxic stress.
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compensatory mechanism supporting the functional integ-
rity of the diaphragm muscle. NAC pretreatment enhanced
the endogenous induction of Akt signalling, potentially
bolstering the cellular defences against acute hypoxic stress.
This may be (part of) the mechanism by which NAC rescues
diaphragm force in acute hypoxia. It is also worth noting that
Akt/mTOR signalling can regulate HIF-1α and may play a
role in hypoxia-induced HIF-1α expression [52–54]. Akt
also exerts prohypertrophic eﬀects via inhibition of atrophic
signalling (Figure 12).
Phospho-p70S6K, which is downstream of Akt, was
slightly elevated by acute hypoxia in the diaphragm. Its
protein content was, however, signiﬁcantly elevated in the
hypoxic diaphragm by NAC supplementation. p70S6k acti-
vation by Akt is mediated via the indirect activation of
mTOR by Akt. p70S6K, when activated, promotes transla-
tion/protein synthesis and cell survival in muscle [55–57].
The fact that the induction of elevated phospho-p70S6K is
greater in hypoxia +NAC compared with hypoxia alone is
likely due to the greater elevation of phospho-Akt, phos-
pho-mTOR, and phospho-ERK1/2 in hypoxia +NAC, which
all activate phospho-p70S6K [58]. Again, this is indicative of
prohypertrophy signalling induced by NAC supplementa-
tion, a mechanism which appears beneﬁcial in the mainte-
nance of diaphragm muscle performance. Indeed, decreased
phospho-p70S6K expression occurs in the diaphragm of
mechanically ventilated rats prior to decreased protein syn-
thesis [59].
Phospho-S6RP content, which is a downstream of
both Akt/mTOR and p70S6K, was signiﬁcantly increased
in the diaphragm both by hypoxia and hypoxia +NAC.
The phosphorylation of S6RP by phospho-p70S6K, driven
by Akt/mTOR, drives translation/protein synthesis and
growth (Figure 12).
Hypoxia can activate Akt leading to GSK-3 phosphoryla-
tion [49]. Phosphorylation negatively regulates GSK-3β,
inhibiting it, resulting in the activation of protein synthesis
and a cessation of antianabolic signalling from GSK-3β. In
our study, phospho-GSK-3β protein content was increased
signiﬁcantly by hypoxia and increased further still by hyp-
oxia +NAC. Again, these data suggest a drive toward a pro-
hypertrophic/proprotein synthesis state in acute hypoxia
that is further augmented by NAC pretreatment.
4.5.2. mTOR Pathway.mTOR is a protein kinase functioning
in the regulation of growth, survival, and protein synthesis in
skeletal muscle. Both mTOR and phospho-mTOR were mea-
sured in our study. mTORmediates its hypertrophic/cell sur-
vival signalling eﬀects via its phosphorylated/activated state.
Acute hypoxia signiﬁcantly increased mTOR protein con-
tent. Whereas hypoxia and hypoxia +NAC both increased
phospho-mTOR protein content, expression was greatest in
the hypoxia +NAC group. It appears that hypoxia alone, in
the absence of NAC, induces an increase in mTOR protein
expression, or indeed a reduction in mTOR degradation,
while phosphorylation of mTOR is induced by hypoxia,
and to a greater extent by hypoxia concomitant with NAC
supplementation. Phospho-p70S6K and phospho-s6RP, dis-
cussed above, are also both downstream of, and activated
by, mTOR, and so the increase in phospho-mTOR observed
in our study likely contributes to the increases in phospho-
p70S6K and phospho-s6RP reported above.
4.5.3. MAPK Pathway. ERK1/2 is a member of the
MAPK family which positively regulates p70S6K, negatively
regulates GSK-3β, and itself positively regulates cellular pro-
liferation, survival, and development. Through these mecha-
nisms, it is procell survival/hypertrophy. Here, acute hypoxia
increased diaphragm phospho-ERK1/2 protein content, and
NAC pretreatment further augmented phospho-ERK1/2
protein content. This, combined with changes in Akt signal-
ling described above, is further suggestive that NAC pretreat-
ment bolsters the endogenous cellular signalling mechanisms
acting to promote protein synthesis and cell survival in the
acutely hypoxic diaphragm.
4.5.4. FoxO3a Pathway. The FoxO pathway is generally asso-
ciated with atrophy and protein degradation in its dephos-
phorylated state. However, when phosphorylated, FoxO3a
is inhibited from translocation into the nucleus and exerting
its atrophic eﬀects. One mechanism by which Akt exerts a
hypertrophic eﬀect is by the phosphorylation and thus inhi-
bition of FoxO3a, preventing the atrophic action of the atro-
genes MuRF-1 and Atrogin-1, which would otherwise be
transcriptionally upregulated by FoxO3a. Our study revealed
that acute hypoxia increases phospho-FoxO3a protein
content in the diaphragm and NAC pretreatment further
augmented phosphoprotein content, thus enhancing the
prohypertrophic/antiatrophic signalling cascades described
above, via the downregulation of FoxO3a-induced proteaso-
mal and autophagy-mediated protein degradation. The acute
hypoxia-induced increase in phosphoprotein content is likely
mediated via the increase in phospho-Akt.
4.6. Proatrophy/Cell Death Signalling
4.6.1. MAPK Pathway. While there appears to be a predom-
inant drive toward protein synthesis in the acutely hypoxic
diaphragm, augmented further by NAC pretreatment, there
is also an increase in atrophic signalling via the MAPK path-
way. JNK promotes autophagy, apoptosis, inﬂammation, and
cell death and is activated by phosphorylation [60]. We
observed that acute hypoxia elevated diaphragm levels of
phospho-JNK protein, an eﬀect which is further augmented
by NAC supplementation. This is somewhat surprising given
that Akt, which is also activated, negatively regulates the JNK
pathway via a cross-talk mechanism [61]. JNK phosphoryla-
tion in our model is therefore likely induced by some other
mechanism/stress aﬀecting theMAPK pathway. p38 can pro-
mote inﬂammation and apoptosis, while also negatively reg-
ulating GSK-3β to promote survival [62]. In our study, acute
hypoxia increased diaphragm phospho-p38 expression to
near signiﬁcant levels in the diaphragm, while NAC concom-
itant with acute hypoxia signiﬁcantly augmented this
response. This suggests a proatrophic eﬀect of hypoxia
+NAC in the diaphragm. We acknowledge that our assess-
ment of apoptotic pathways is incomplete.
We observed no change in autophagy gene expression.
We do not have information on autophagy signalling at the
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protein level, but this is an area worthy of further pursuit. We
observed no change in the expression of several atrogenes,
but there was an increase in the mRNA expression of FoxO3
andMuRF-1 in the diaphragm after 8 hours of hypoxia expo-
sure. Despite this apparent increase in atrophy signalling,
there was no downstream change in diaphragm proteasome
enzymatic activity, suggesting that protein catabolism did
not occur, at least not within 8 hours of hypoxic stress, which
suggested that diaphragm muscle weakness in hypoxia is not
likely related to muscle ﬁbre atrophy, a phenomenon that has
been observed in respiratory muscles following chronic sus-
tained hypoxic exposure [13, 14]. Immunohistochemical
analysis of diaphragm muscle ﬁbre size and distribution
revealed that acute sustained hypoxia did not cause myoﬁbre
atrophy or a shift in the size distribution of ﬁbres. Therefore,
we conclude that myoﬁbre contractile dysfunction underpins
diaphragm weakness following acute hypoxia, a phenome-
non that has been reported, in addition to ﬁbre atrophy, in
diaphragm in response to chronic sustained hypoxia [63].
We employed a TBARS assay as a measure of muscle
lipid peroxidation. We acknowledge the limitation of this
measurement as an index of oxidative stress. Malondialde-
hyde is generated only by certain lipid peroxidation products,
and it is not generated exclusively by lipid peroxidation.
Exposure to acute hypoxia resulted in a modest but signiﬁ-
cant increase in diaphragm malondialdehyde, which we
interpret as indicative of oxidative stress, but this needs to
be conﬁrmed in future studies. Although the source of reac-
tive oxygen species was not determined in our study, the
inhibitory eﬀects of reactive oxygen species on striated
muscle force-generating capacity are well described [64–66].
Pretreatment with NAC completely reversed the hypoxia-
induced increase in diaphragm lipid peroxidation, decreas-
ing TBARS levels to below control values. This reveals the
antioxidant capacity of NAC and suggests that some of its
inotropic action in diaphragm muscle exposed to hypoxia
most likely related to suppression of hypoxia-induced oxida-
tive stress. We acknowledge that the eﬀects of NAC pretreat-
ment were not determined in all experiments.
5. Conclusions
Figure 12 provides an overview of the eﬀects of acute hypoxia
on diaphragm protein signaling pathways pivotal to protein
turnover and cell survival. Our study determined that acute
hypoxic stress of just several hours is suﬃcient to cause dia-
phragm weakness, which may have clinical relevance.
Hypoxia-induced diaphragm dysfunction is prevented by
NAC pretreatment, via a mechanism independent of hypoxic
hypometabolism in mice. We previously demonstrated that
exposure to acute hypoxia increases UCP-3 mRNA expres-
sion in the mouse diaphragm suggesting an increased reli-
ance on fatty acid metabolism [17, 18]. However, in the
present study, we determined that the respiratory exchange
ratio is unaﬀected by acute hypoxia, suggesting that there is
no switch in metabolic energy source; the ratio of 0.7 reveals
that fatty acids are the primary substrate for oxidative metab-
olism and energy production in normoxic mice, and this is
unaltered by hypoxic exposure. This diﬀers from the
pronounced metabolic remodelling that occurs in respiratory
muscles exposed to chronic sustained hypoxia [15, 16]. The
hypoxia-induced increase in UCP-3 [17] may therefore be a
compensatory mechanism to reduce ROS production and
oxidative stress. Nevertheless, acute hypoxia results in dia-
phragm muscle oxidative stress, which is likely implicated
in the elaboration of diaphragm weakness. Hypoxia did not
cause any persistent change in ventilation (diaphragm mus-
cle activity), and therefore muscle weakness and molecular
changes are likely directly related to hypoxic stress per se
and unrelated to altered mechanical work in hypoxia, though
this may be a factor in other mammals such as humans. NAC
pretreatment potentiates endogenous cell survival signalling
and prevents hypoxia-induced diaphragm oxidative stress.
The drive to increase both hypertrophy and atrophy signal-
ling may be required to increase protein turnover and amino
acid-dependent ATP generation, but notably diaphragm
myoﬁbre size and distribution are unaﬀected. NAC appears
to boost endogenous cell survival signalling cascades potenti-
ating defence responses, perhaps in this way preserving dia-
phragm function in the face of redox stress, in addition to
established antioxidant actions. Our ﬁndings highlight the
potentially critical role of hypoxic stress as a contributor to
diaphragm myoﬁbre dysfunction in respiratory patients.
Our results may also have relevance to respiratory muscle
performance at high altitude. On the basis of our ﬁndings
in an animal model, we conclude that NAC may be a beneﬁ-
cial adjunctive therapy in patients, alleviating hypoxia-
induced diaphragm dysfunction, potentially improving
patient outcome.
Conflicts of Interest
The authors declare that they have no conﬂicts of interest.
Authors’ Contributions
Andrew J. O’Leary and Ken D. O’Halloran conceived and
designed the study. Andrew J. O’Leary performed all experi-
ments and data analysis, except for the TBARS assay, which
was performed and analyzed by Sarah E. Drummond, and
immunohistochemistry, which was performed and analyzed
by Deirdre Edge. All authors approved the ﬁnal version of
the manuscript.
Acknowledgments
Ken D. O’Halloran received a Strategic Research Award from
University College Cork. Andrew J. O’Leary was supported
by the Department of Physiology, University College Cork.
The authors are grateful to the staﬀs of the Biological Services
Unit, UCC, for the support with animal care and welfare. The
authors are grateful to Dr. Greg Jasionek, Department of
Physiology, UCC, for technical support.
References
[1] G. S. Supinski and L. A. Callahan, “Diaphragm weakness in
mechanically ventilated critically ill patients,” Critical Care,
vol. 17, no. 3, article R120, 2013.
16 Oxidative Medicine and Cellular Longevity
[2] M. B. Hudson, A. J. Smuder, W. B. Nelson, C. S. Bruells,
S. Levine, and S. K. Powers, “Both high level pressure support
ventilation and controlled mechanical ventilation induce dia-
phragm dysfunction and atrophy,” Critical Care Medicine,
vol. 40, no. 4, pp. 1254–1260, 2012.
[3] A. N. Kavazis, E. E. Talbert, A. J. Smuder, M. B. Hudson, W. B.
Nelson, and S. K. Powers, “Mechanical ventilation induces dia-
phragmatic mitochondrial dysfunction and increased oxidant
production,” Free Radical Biology & Medicine, vol. 46, no. 6,
pp. 842–850, 2009.
[4] J. Doorduin, J. Leentjens, M. Kox et al., “Eﬀects of experimen-
tal human endotoxemia on diaphragm function,” Shock,
vol. 44, no. 4, pp. 316–322, 2015.
[5] G. S. Supinski, A. P. Alimov, L. Wang, X. H. Song, and L. A.
Callahan, “Calcium-dependent phospholipase A2 modulates
infection-induced diaphragm dysfunction,” American Journal
of Physiology Lung Cell Molecular Physiology, vol. 310,
no. 10, pp. L975–L984, 2016.
[6] A. H. Jonkman, D. Jansen, and L. M. Heunks, “Novel insights
in ICU-acquired respiratory muscle dysfunction: implications
for clinical care,” Critical Care, vol. 21, no. 1, p. 64, 2017.
[7] A. V. Namuduri, G. Heras, J. Mi et al., “A proteomic approach
to identify alterations in the SUMO network during controlled
mechanical ventilation in rat diaphragmmuscle,”Molecular &
Cell Proteomics, vol. 16, no. 6, pp. 1081–1097, 2017.
[8] I. Azuelos, B. Jung, M. Picard et al., “Relationship between
autophagy and ventilator-induced diaphragmatic dysfunc-
tion,” Anesthesiology, vol. 122, no. 6, pp. 1349–1361, 2015.
[9] S. K. Powers, M. B. Hudson, W. B. Nelson et al., “Mito-
chondria-targeted antioxidants protect against mechanical
ventilation-induced diaphragm weakness,” Critical Care Med-
icine, vol. 39, no. 7, pp. 1749–1759, 20111759, 2011.
[10] J. Wu and S. T. Li, “Dexmedetomidine may produce extra pro-
tective eﬀects on sepsis-induced diaphragm injury,” Chinese
Medical Journal, vol. 128, no. 10, pp. 1407–1411, 2015.
[11] G. S. Supinski and L. A. Callahan, “Free radical-mediated
skeletal muscle dysfunction in inﬂammatory conditions,”
Journal of Applied Physiology, vol. 102, no. 5, pp. 2056–2063,
2007.
[12] S. K. Powers, M. P. Wiggs, K. J. Sollanek, and A. J. Smuder,
“Ventilator-induced diaphragm dysfunction: cause and eﬀect,”
American Journal of Physiology-Regulatory Integrative and
Comparative Physiology, vol. 305, no. 5, pp. R464–R477, 2013.
[13] C. McMorrow, A. Fredsted, J. Carberry et al., “Chronic
hypoxia increases rat diaphragm muscle endurance and
sodium-potassium ATPase pump content,” European Respira-
tory Journal, vol. 37, no. 6, pp. 1474–1481, 2011.
[14] J. L. Gamboa and F. H. Andrade, “Muscle endurance and
mitochondrial function after chronic normobaric hypoxia:
contrast of respiratory and limb muscles,” Pﬂügers Archiv -
European Journal of Physiology, vol. 463, no. 2, pp. 327–338,
2012.
[15] P. Lewis, D. Sheehan, R. Soares, A. Varela Coelho, and
K. D. O’Halloran, “Chronic sustained hypoxia-induced redox
remodeling causes contractile dysfunction in mouse sterno-
hyoid muscle,” Frontiers in Physiology, vol. 6, p. 122, 2015.
[16] P. Lewis, D. Sheehan, R. Soares, A. V. Coelho, and K. D.
O’Halloran, “Redox remodeling is pivotal in murine dia-
phragm muscle adaptation to chronic sustained hypoxia,”
American Journal of Respiratory Cell and Molecular Biology,
vol. 55, no. 1, pp. 12–23, 2016.
[17] A. J. O’Leary and K. D. O’Halloran, “Diaphragmmuscle weak-
ness and increased UCP-3 gene expression following acute
hypoxic stress in the mouse,” Respiratory Physiology & Neuro-
biology, vol. 226, pp. 76–80, 2016.
[18] A. J. O’Leary, Acute Hypoxia-Induced Diaphragm Dysfunction
Is Prevented by Antioxidant Pre-Treatment, [Ph.D. thesis],
University College Cork, Ireland, 2017, https://cora.ucc.ie/
bitstream/handle/10468/3895/O'LearyAJ_PhD2017.pdf.
[19] R. Pellegrino, G. Deboeck, J. J. Moraine, and R. Naeije, “Respi-
ratory muscle strength may explain hypoxia-induced decrease
in vital capacity,” Medicine & Science in Sports & Exercise,
vol. 26, pp. 754–758, 2005.
[20] S. Sharma and B. Brown, “Spirometry and respiratory muscle
function during ascent to higher altitudes,” Lung, vol. 185,
no. 2, pp. 113–121, 2007.
[21] P. Lewis and K. D. O'Halloran, “Diaphragm muscle adapta-
tion to sustained hypoxia: lessons from animal models with
relevance to high altitude and chronic respiratory diseases,”
Frontiers in Physiology, vol. 7, p. 623, 2016.
[22] R. Campos, M. H. M. Shimizu, R. A. Volpini et al., “N-acet-
ylcysteine prevents pulmonary edema and acute kidney
injury in rats with sepsis submitted to mechanical ventilation,”
American Journal of Physiology Lung Cellular and Molecular
Physiology, vol. 302, no. 7, pp. L640–L650, 2012.
[23] M. Cazzola, L. Calzetta, C. Page et al., “Inﬂuence of N-
acetylcysteine on chronic bronchitis or COPD exacerbations:
a meta-analysis,” European Respiratory Review, vol. 24,
no. 137, pp. 451–461, 2015.
[24] C. Conrad, J. Lymp, V. Thompson et al., “Long-term treatment
with oral N-acetylcysteine: aﬀects lung function but not spu-
tum inﬂammation in cystic ﬁbrosis subjects. A phase II ran-
domized placebo-controlled trial,” Journal of Cystic Fibrosis,
vol. 14, no. 2, pp. 219–227, 2015.
[25] B. J. Day, “Antioxidants as potential therapeutics for lung
ﬁbrosis,” Antioxidant & Redox Signaling, vol. 10, no. 2,
pp. 355–370, 2008.
[26] M. Skov, T. Pressler, J. Lykkesfeldt et al., “The eﬀect of short-
term, high-dose oral N-acetylcysteine treatment on oxidative
stress markers in cystic ﬁbrosis patients with chronic P. aeru-
ginosa infection - a pilot study,” Journal of Cystic Fibrosis,
vol. 14, no. 2, pp. 211–218, 2015.
[27] P.M. Suter, G. Domenighetti, M.-D. Schaller, M.-C. Laverrière,
R. Ritz, and C. Perret, “N-acetylcysteine enhances recovery
from acute lung injury in man,” Chest Journal, vol. 105,
no. 1, pp. 190–194, 1994.
[28] V. M. Víctor, J. V. Espulgues, A. Hernández-Mijares, and
M. Rocha, “Oxidative stress and mitochondrial dysfunction
in sepsis: a potential therapy with mitochondria-targeted anti-
oxidants,” Infectious Disorders Drug Targets, vol. 9, no. 4,
pp. 376–389, 2009.
[29] S. Levine, M. H. Bashir, T. L. Clanton, S. K. Powers, and
S. Singhal, “COPD elicits remodeling of the diaphragm and
vastus lateralis muscles in humans,” Journal of Applied Physi-
ology, vol. 114, no. 9, pp. 1235–1245, 2013.
[30] M. Klimathianaki, K. Vaporidi, and D. Georgopoulos,
“Respiratory muscle dysfunction in COPD: from muscles
to cell,” Current Drug Targets, vol. 12, no. 4, pp. 478–488,
2011.
[31] M. Dunleavy, A. Bradford, and K. D. O’Halloran, “Oxida-
tive stress impairs upper airway muscle endurance in an
animal model of sleep-disordered breathing,” Advances in
17Oxidative Medicine and Cellular Longevity
Experimental Medicine and Biology, vol. 605, pp. 458–462,
2008.
[32] C. M. Shortt, A. Fredsted, H. B. Chow et al., “Reactive oxygen
species mediated diaphragm fatigue in a rat model of chronic
intermittent hypoxia,” Experimental Physiology, vol. 99,
no. 4, pp. 688–700, 2014.
[33] M. S. Soltan-Shariﬁ, M. Mojtahedzadeh, A. Najaﬁ et al.,
“Improvement by N-acetylcysteine of acute respiratory dis-
tress syndrome through increasing intracellular glutathione,
and extracellular thiol molecules and anti-oxidant power: evi-
dence for underlying toxicological mechanisms,” Human &
Experimental Toxicology, vol. 26, no. 9, pp. 697–703, 2007.
[34] J. Magalhães, A. Ascensão, J. M. C. Soares et al., “Acute and
severe hypobaric hypoxia increases oxidative stress and
impairs mitochondrial function in mouse skeletal muscle,”
Journal of Applied Physiology, vol. 99, no. 4, pp. 1247–1253,
2005.
[35] M. A. Smith and M. B. Reid, “Redox modulation of contractile
function in respiratory and limb skeletal muscle,” Respiratory
Physiology & Neurobiology, vol. 151, no. 2-3, pp. 229–241,
2006.
[36] Y. B. Seven, C. B. Mantilla, and G. C. Sieck, “Recruitment of rat
diaphragm motor units across motor behaviors with diﬀerent
levels of diaphragm activation,” Journal of Applied Physiology,
vol. 117, no. 11, pp. 1308–1316, 2014.
[37] P. Lewis, C. McMorrow, A. Bradford, and K. D. O’Halloran,
“Improved tolerance of acute severe hypoxic stress in chronic
hypoxic diaphragm is nitric oxide-dependent,” The Journal
of Physiological Sciences, vol. 65, no. 5, pp. 427–433, 2015.
[38] A. Agten, K. Maes, A. Smuder, S. K. Powers, M. Decramer,
and G. Gayan-Ramirez, “N-acetylcysteine protects the rat dia-
phragm from the decreased contractility associated with
controlled mechanical ventilation,” Critical Care Medicine,
vol. 39, no. 4, pp. 777–782, 2011.
[39] E. Barreiro, “Role of protein carbonylation in skeletal muscle
mass loss associated with chronic conditions,” Proteomes,
vol. 4, no. 2, p. 18, 2016.
[40] S. Bonello, C. Zähringer, R. S. BelAiba et al., “Reactive oxygen
species activate the HIF-1α promoter via a functional NFκB
site,” Arteriosclerosis Thrombosis, and Vascular Biology,
vol. 27, no. 4, pp. 755–761, 2007.
[41] S. W. Jusman, A. Halim, S. I. Wanandi, and M. Sadikin,
“Expression of hypoxia-inducible factor-1α (HIF-1α) related
to oxidative stress in liver of rat-induced by systemic chronic
normobaric hypoxia,” Acta Medica Indonesia, vol. 42,
pp. 17–23, 2010.
[42] H. Niecknig, S. Tug, B. D. Reyes, M. Kirsch, J. Fandrey,
and U. Berchner-Pfannschmidt, “Role of reactive oxygen
species in the regulation of HIF-1 by prolyl hydroxylase 2
under mild hypoxia,” Free Radical Research, vol. 46, no. 6,
pp. 705–717, 2012.
[43] M. Schieber and N. S. Chandel, “ROS function in redox signal-
ing and oxidative stress,” Current Biology, vol. 24, no. 10,
pp. R453–R462, 2014.
[44] W. S. Jin, Z. L. Kong, Z. F. Shen, Y. Z. Jin, W. K. Zhang, and
G. F. Chen, “Regulation of hypoxia inducible factor-1α expres-
sion by the alteration of redox status in HepG2 cells,” Journal
of Experimental & Clinical Cancer Research, vol. 30, no. 1,
p. 61, 2011.
[45] M. Nikinmaa, S. Pursiheimo, and A. J. Soitamo, “Redox state
regulates HIF-1α and its DNA binding and phosphorylation
in salmonid cells,” Journal of Cell Science, vol. 117, no. 15,
pp. 3201–3206, 2004.
[46] J. Sceneay, M. C. P. Liu, A. Chen, C. S. F. Wong, D. D. L.
Bowtell, and A. Möller, “The antioxidant N-acetylcysteine
prevents HIF-1 stabilization under hypoxia in vitro but does
not aﬀect tumorigenesis in multiple breast cancer models
in vivo,” PLoS One, vol. 8, no. 6, article e66388, 2013.
[47] Z. Zhang, J. Yan, S. Taheri, K. J. Liu, and H. Shi, “Hypoxia-
inducible factor 1 contributes to N-acetylcysteine’s protection
in stroke,” Free Radical Biology & Medicine, vol. 68, pp. 8–
21, 2014.
[48] M. Alvarez-Tejado, S. Naranjo-Suarez, C. Jiménez et al., “Hyp-
oxia induces the activation of the phosphatidylinositol 3-
kinase/Akt cell survival pathway in PC12 cells: protective role
in apoptosis,” Journal of Biological Chemistry, vol. 276, no. 25,
pp. 22368–22374, 2001.
[49] D. Beitner-Johnson, R. T. Rust, T. C. Hsieh, and D. E. Mill-
horn, “Hypoxia activates Akt and induces phosphorylation of
GSK-3 in PC12 cells,” Cellular Signalling, vol. 13, no. 1,
pp. 23–27, 2001.
[50] T. Dai, H. Zheng, and G. Fu, “Hypoxia confers protection
against apoptosis via the PI3K/Akt pathway in endothelial
progenitor cells,” Acta Pharmacologica Sinica, vol. 29, no. 12,
pp. 1425–1431, 2008.
[51] H. Stegeman, J. H. Kaanders, D. L. Wheeler et al., “Activation
of AKT by hypoxia: a potential target for hypoxic tumors of
the head and neck,” BMC Cancer, vol. 12, no. 1, p. 463, 2012.
[52] M. Kilic-Eren, T. Boylu, and V. Tabor, “Targeting PI3K/Akt
represses hypoxia inducible factor-1α activation and sensitizes
rhabdomyosarcoma and Ewing’s sarcoma cells for apoptosis,”
Cancer Cell International, vol. 13, no. 1, p. 36, 2013.
[53] S. C. Land and A. R. Tee, “Hypoxia-inducible factor 1α is reg-
ulated by the mammalian target of rapamycin (mTOR) via an
mTOR signaling motif,” Journal of Biological Chemistry,
vol. 282, no. 28, pp. 20534–20543, 2007.
[54] X. M. Yang, Y. S. Wang, J. Zhang et al., “Role of PI3K/Akt
and MEK/ERK in mediating hypoxia-induced expression of
HIF-1α and VEGF in laser-induced rat choroidal neovascu-
larization,” Investigative Ophthalmology & Visual Science,
vol. 50, no. 4, pp. 1873–1879, 2009.
[55] K. Baar and K. Esser, “Phosphorylation of p70S6k correlates
with increased skeletal muscle mass following resistance exer-
cise,” American Journal of Physiology Cell Physiology, vol. 276,
no. 1, pp. C120–C127, 1999.
[56] P. Gran, A. E. Larsen, M. Bonham et al., “Muscle p70S6K
phosphorylation in response to soy and dairy rich meals in
middle aged men with metabolic syndrome: a randomised
crossover trial,” Nutrition & Metabolism, vol. 11, no. 1, p. 46,
2014.
[57] N. E. Zanchi and A. H. Lancha, “Mechanical stimuli of skeletal
muscle: implications onmTOR/p70s6k and protein synthesis,”
European Journal of Applied Physiology, vol. 102, no. 3,
pp. 253–263, 2008.
[58] J. G. Krolikowski, D. Weihrauch, M. Bienengraeber, J. R.
Kersten, D. C. Warltier, and P. S. Pagel, “Role of Erk1/2,
p70s6K, and eNOS in isoﬂurane-induced cardioprotection
during early reperfusion in vivo,” Canadian Journal of Anes-
thesiology, vol. 53, no. 2, pp. 174–182, 2006.
[59] J. M. McClung, M. A. Whidden, A. N. Kavazis, D. J. Falk, K. C.
Deruisseau, and S. K. Powers, “Redox regulation of diaphragm
proteolysis during mechanical ventilation,” American Journal
18 Oxidative Medicine and Cellular Longevity
of Physiology Regulatory, Integrative and Comparative Physiol-
ogy, vol. 294, no. 5, pp. R1608–R1617, 2008.
[60] A. Berdichevsky, L. Guarente, and A. Bose, “Acute oxidative
stress can reverse insulin resistance by inactivation of cytoplas-
mic JNK,” Journal of Biological Chemistry, vol. 285, no. 28,
pp. 21581–21589, 2010.
[61] V. Levresse, L. Butterﬁeld, E. Zentrich, and L. E. Heasley, “Akt
negatively regulates the cJun N-terminal kinase pathway in
PC12 cells,” Journal of Neuroscience Research, vol. 62, no. 6,
pp. 799–808, 2000.
[62] T. M. Thornton, G. Pedraza-Alva, B. Deng et al., “Phosphory-
lation by p38 MAPK as an alternative pathway for GSK3beta
inactivation,” Science, vol. 320, no. 5876, pp. 667–670, 2008.
[63] H. Degens, A. Bosutti, S. F. Gilliver, M. Slevin, A. van Heijst,
and R. C. Wust, “Changes in contractile properties of skinned
single rat soleus and diaphragm ﬁbres after chronic hypoxia,”
Pﬂügers Archiv - European Journal of Physiology, vol. 460,
no. 5, pp. 863–873, 2010.
[64] T. L. Clanton, “Hypoxia-induced reactive oxygen species for-
mation in skeletal muscle,” Journal of Applied Physiology,
vol. 102, no. 6, pp. 2379–2388, 2007.
[65] L. Zuo, T. M. Best, W. J. Roberts, P. T. Diaz, and P. D. Wagner,
“Characterization of reactive oxygen species in diaphragm,”
Acta Physiologica, vol. 213, no. 3, pp. 700–710, 2015.
[66] M. B. Reid and J. S. Moylan, “Beyond atrophy: redox mecha-
nisms of muscle dysfunction in chronic inﬂammatory disease,”
The Journal of Physiology, vol. 589, no. 9, pp. 2171–2179, 2011.
19Oxidative Medicine and Cellular Longevity
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
